CN110051836B - 使用膜stim1筛选化合物的方法 - Google Patents

使用膜stim1筛选化合物的方法 Download PDF

Info

Publication number
CN110051836B
CN110051836B CN201910160451.4A CN201910160451A CN110051836B CN 110051836 B CN110051836 B CN 110051836B CN 201910160451 A CN201910160451 A CN 201910160451A CN 110051836 B CN110051836 B CN 110051836B
Authority
CN
China
Prior art keywords
stim1
cells
leu
ser
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910160451.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110051836A (zh
Inventor
伊夫·勒诺迪诺
奥利维耶·米尼昂
米格尔·比尔戈斯
雅克·奥利维耶·佩斯
廷希南·法利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
French National Institute Of Health And Medicine
Univerdite de Bretagne Occidentale
CHU DE BREST
Original Assignee
French National Institute Of Health And Medicine
Univerdite de Bretagne Occidentale
CHU DE BREST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by French National Institute Of Health And Medicine, Univerdite de Bretagne Occidentale, CHU DE BREST filed Critical French National Institute Of Health And Medicine
Priority to CN201910160451.4A priority Critical patent/CN110051836B/zh
Publication of CN110051836A publication Critical patent/CN110051836A/zh
Application granted granted Critical
Publication of CN110051836B publication Critical patent/CN110051836B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201910160451.4A 2014-08-06 2015-07-31 使用膜stim1筛选化合物的方法 Active CN110051836B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910160451.4A CN110051836B (zh) 2014-08-06 2015-07-31 使用膜stim1筛选化合物的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14290232.9A EP2982982B1 (en) 2014-08-06 2014-08-06 Method of screening of compounds using membrane STIM1
EP14290232.9 2014-08-06
CN201910160451.4A CN110051836B (zh) 2014-08-06 2015-07-31 使用膜stim1筛选化合物的方法
CN201580042267.XA CN106716130B (zh) 2014-08-06 2015-07-31 使用膜stim1筛选化合物的方法
PCT/EP2015/067615 WO2016020274A1 (en) 2014-08-06 2015-07-31 Method of screening of compounds using membrane stim1

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580042267.XA Division CN106716130B (zh) 2014-08-06 2015-07-31 使用膜stim1筛选化合物的方法

Publications (2)

Publication Number Publication Date
CN110051836A CN110051836A (zh) 2019-07-26
CN110051836B true CN110051836B (zh) 2023-05-26

Family

ID=51398585

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910160451.4A Active CN110051836B (zh) 2014-08-06 2015-07-31 使用膜stim1筛选化合物的方法
CN201580042267.XA Expired - Fee Related CN106716130B (zh) 2014-08-06 2015-07-31 使用膜stim1筛选化合物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580042267.XA Expired - Fee Related CN106716130B (zh) 2014-08-06 2015-07-31 使用膜stim1筛选化合物的方法

Country Status (11)

Country Link
US (2) US20170219588A1 (enExample)
EP (2) EP2982982B1 (enExample)
JP (2) JP6754751B2 (enExample)
CN (2) CN110051836B (enExample)
CA (1) CA2952159C (enExample)
DK (1) DK2982982T3 (enExample)
ES (1) ES2654674T3 (enExample)
NO (1) NO2982982T3 (enExample)
PL (1) PL2982982T3 (enExample)
PT (1) PT2982982T (enExample)
WO (1) WO2016020274A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3715848A1 (en) * 2019-03-25 2020-09-30 Université de Bretagne Occidentale (U.B.O.) Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods
EP3714942A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
EP3714943A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
US20240083990A1 (en) * 2021-01-26 2024-03-14 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102433383A (zh) * 2011-12-19 2012-05-02 上海吉凯基因化学技术有限公司 人stim1基因的用途及其相关药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101223448B (zh) * 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
WO2008148108A1 (en) * 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
JP5559049B2 (ja) * 2007-07-10 2014-07-23 チルドレンズ メディカル センター コーポレーション 間質相互作用分子ノックアウトマウス及びその使用
WO2009021338A1 (en) * 2007-08-15 2009-02-19 UNIVERSITé DE SHERBROOKE Alternative splicing gene variants in cancer detection
US8263641B2 (en) * 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2103311A1 (en) * 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
US20120165265A1 (en) * 2009-02-26 2012-06-28 Dolmetsch Ricardo E Calcium Signaling Modulators Involving STIM and ORAI Proteins
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
EP2723382A4 (en) * 2011-08-10 2015-03-04 Wilfred A Jefferies METHOD AND COMPOSITIONS FOR MODULATING A VOLTAGE-CONTROLLED CALCIUM CHANNEL FUNCTION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102433383A (zh) * 2011-12-19 2012-05-02 上海吉凯基因化学技术有限公司 人stim1基因的用途及其相关药物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Abnormal Calcium Influx in T and B Lymphocytes from Systemic Lupus Erythematosus Patients is Related to STIM-1 Over-Expression;Yves Renaudineau等;《Ann Rheum Dis》;20131231;第72卷(第Suppl 1期);第A30页 *
Maria A.Spassova等.STIM1 has a plasma membrane role in the activation of store-operated Ca2+ channels.《PNAS》.2006,第103卷(第11期), *
STIM1 has a plasma membrane role in the activation of store-operated Ca2+ channels;Maria A.Spassova等;《PNAS》;20060314;第103卷(第11期);第4040-4045页 *
stromal interaction molecule 1 isoform 2 precursor [Homo sapiens]，NP_003147.2;Hartmann J等;《NCBI》;20140722;第1-3页 *
卢根娣等.第八章 风湿性疾病患者的护理.《内科护理学》.第二军医大学出版社,2013, *

Also Published As

Publication number Publication date
NO2982982T3 (enExample) 2018-03-03
CA2952159A1 (en) 2016-02-11
CN106716130A (zh) 2017-05-24
JP6861246B2 (ja) 2021-04-21
JP6754751B2 (ja) 2020-09-16
US20190154690A1 (en) 2019-05-23
JP2017531164A (ja) 2017-10-19
WO2016020274A1 (en) 2016-02-11
CN106716130B (zh) 2019-03-29
CA2952159C (en) 2022-08-30
US20170219588A1 (en) 2017-08-03
DK2982982T3 (en) 2018-01-08
JP2019214576A (ja) 2019-12-19
EP3177929B1 (en) 2018-05-09
PT2982982T (pt) 2018-01-03
CN110051836A (zh) 2019-07-26
EP3177929A1 (en) 2017-06-14
EP2982982B1 (en) 2017-10-04
ES2654674T3 (es) 2018-02-14
PL2982982T3 (pl) 2018-03-30
EP2982982A1 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
McMahon et al. SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function
Bourguignon et al. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor β receptor I in metastatic breast tumor cells
Mousavi et al. Receptor‐mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcγRIIb2
JP5855569B2 (ja) 破骨細胞特異的抗原の生物学的活性を特異的にブロックする抗体
Ho et al. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-κB-dependent proliferative advantage and resistance against FAS-induced cell death in B cells
Qian et al. Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis
Xu et al. Induction of osteogenesis by bone-targeted Notch activation
Mansuy et al. GEC1, a protein related to GABARAP, interacts with tubulin and GABAA receptor
WO2008103849A2 (en) Methods and compounds for lymphoma cell detection and isolation
CN114019156A (zh) 免疫突触的质量预测了嵌合抗原受体（car）t细胞的效能
CN110051836B (zh) 使用膜stim1筛选化合物的方法
Machtaler et al. The gap junction protein Cx43 regulates B-lymphocyte spreading and adhesion
KR20080059449A (ko) 치료용 약제
Kwon et al. Orphan G protein-coupled receptor GPRC5B controls macrophage function by facilitating prostaglandin E receptor 2 signaling
Li et al. A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma
Yaroslavskiy et al. Functional osteoclast attachment requires inositol-1, 4, 5-trisphosphate receptor-associated cGMP-dependent kinase substrate
Tremblay et al. The membrane proximal proline-rich region and correct order of C-terminal tyrosines on the adaptor protein LAT are required for TCR-mediated signaling and downstream functions
Hynes et al. Inhibition of Gαs/cAMP signaling decreases TCR-stimulated IL-2 transcription in CD4+ T helper cells
EP1294872B1 (en) Human trp-like calcium channel protein-2 (tlcc-2)
JP7570348B2 (ja) 細胞の原形質膜に局在するｓｔｉｍ１画分のｃ末端断片と相互作用する物質、がんの処置、並びにスクリーニング及び診断方法におけるその使用
KR102647295B1 (ko) 암 면역 치료의 효능 예측을 위한 바이오마커 및 이의 용도
į Lscente msrivi–
Kundu et al. A dynamin perspective on endocytosis and coupling to exocytosis
US20100150879A1 (en) Methods for the detection, isolation, and use of lipid phosphate phosphatase-3-positive stem cells
JP2009502172A (ja) グルコース輸送関連遺伝子、ポリペプチド、およびそれらの使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant